Intellia Therapeutics, Inc. (NTLA) Given Consensus Rating of “Buy” by Brokerages
Intellia Therapeutics, Inc. (NASDAQ:NTLA) has received an average rating of “Buy” from the ten brokerages that are covering the stock, Marketbeat Ratings reports. Three analysts have rated the stock with a hold recommendation and six have assigned a buy recommendation to the company. The average 1-year price objective among analysts that have covered the stock in the last year is $26.80.
Several equities analysts have recently commented on the company. Chardan Capital restated a “buy” rating and issued a $20.00 price objective (up from $19.00) on shares of Intellia Therapeutics in a research report on Wednesday, August 2nd. Cann restated a “hold” rating on shares of Intellia Therapeutics in a research report on Tuesday, August 1st. Jefferies Group LLC restated a “buy” rating and issued a $36.00 price objective on shares of Intellia Therapeutics in a research report on Saturday, July 22nd. Oppenheimer Holdings, Inc. assumed coverage on Intellia Therapeutics in a research report on Tuesday, July 18th. They issued a “market perform” rating on the stock. Finally, TheStreet upgraded Intellia Therapeutics from a “d+” rating to a “c-” rating in a research report on Thursday, July 6th.
In other news, major shareholder Venture Fund Ix L.P. Atlas sold 150,000 shares of Intellia Therapeutics stock in a transaction dated Tuesday, July 11th. The stock was sold at an average price of $16.24, for a total value of $2,436,000.00. The sale was disclosed in a legal filing with the SEC, which is available through the SEC website. Insiders own 12.80% of the company’s stock.
Several large investors have recently modified their holdings of the company. SG Americas Securities LLC purchased a new stake in shares of Intellia Therapeutics during the second quarter valued at about $101,000. IHT Wealth Management LLC bought a new stake in shares of Intellia Therapeutics during the first quarter valued at $117,000. Bank of Montreal Can boosted its stake in shares of Intellia Therapeutics by 1,031.7% in the second quarter. Bank of Montreal Can now owns 7,922 shares of the company’s stock valued at $127,000 after buying an additional 7,222 shares during the last quarter. Nationwide Fund Advisors boosted its stake in shares of Intellia Therapeutics by 117.7% in the second quarter. Nationwide Fund Advisors now owns 8,048 shares of the company’s stock valued at $129,000 after buying an additional 4,351 shares during the last quarter. Finally, Nisa Investment Advisors LLC bought a new stake in shares of Intellia Therapeutics during the second quarter valued at $134,000. 47.20% of the stock is currently owned by hedge funds and other institutional investors.
Intellia Therapeutics (NASDAQ NTLA) opened at 17.10 on Tuesday. The stock’s 50 day moving average price is $16.51 and its 200 day moving average price is $14.36. The company’s market capitalization is $617.52 million. Intellia Therapeutics has a 12 month low of $10.83 and a 12 month high of $24.90.
Intellia Therapeutics (NASDAQ:NTLA) last announced its quarterly earnings data on Thursday, August 3rd. The company reported ($0.45) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.42) by $0.03. Intellia Therapeutics had a negative net margin of 204.48% and a negative return on equity of 22.70%. The business had revenue of $5.90 million during the quarter, compared to analysts’ expectations of $5.83 million. The business’s revenue for the quarter was up 40.5% compared to the same quarter last year. Equities research analysts anticipate that Intellia Therapeutics will post ($1.74) earnings per share for the current fiscal year.
WARNING: “Intellia Therapeutics, Inc. (NTLA) Given Consensus Rating of “Buy” by Brokerages” was published by American Banking News and is the sole property of of American Banking News. If you are reading this article on another publication, it was stolen and reposted in violation of United States & international copyright laws. The correct version of this article can be viewed at https://www.americanbankingnews.com/2017/08/15/intellia-therapeutics-inc-ntla-given-consensus-rating-of-buy-by-brokerages.html.
About Intellia Therapeutics
Intellia Therapeutics, Inc is a genome editing company. The Company is focused on developing therapeutics utilizing a biological tool known as CRISPR/Cas9. The CRISPR/Cas9 genome editing system includes two components: the Cas9 protein and the guide RNA sequence. The Cas9 protein acts like a pair of molecular scissors that initiates the natural cellular repair process to knockout, repair or insert a gene.
Receive News & Ratings for Intellia Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intellia Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.